<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recurrent somatic ASXL1 mutations occur in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, and are associated with adverse outcome </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the genetic and clinical data implicating ASXL1 mutations in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e>, the mechanisms of transformation by ASXL1 mutations are not understood </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we identify that ASXL1 mutations result in loss of polycomb repressive complex 2 (PRC2)-mediated <z:chebi fb="0" ids="15358">histone</z:chebi> H3 lysine 27 (H3K27) tri-methylation </plain></SENT>
<SENT sid="3" pm="."><plain>Through integration of microarray data with genome-wide <z:chebi fb="0" ids="15358">histone</z:chebi> modification ChIP-Seq data, we identify targets of ASXL1 repression, including the posterior HOXA cluster that is known to contribute to myeloid transformation </plain></SENT>
<SENT sid="4" pm="."><plain>We demonstrate that ASXL1 associates with the PRC2, and that loss of ASXL1 inÂ vivo collaborates with NRASG12D to promote myeloid <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
</text></document>